Quantcast

Regenerative Sciences Announces Knee Osteoarthritis Clinical Research Study in Chicago, Illinois

March 14, 2014

New study to measure patient outcomes following non-surgical autologous stem cell procedures for treatment of the common degenerative condition

DENVER, March 14, 2014 /PRNewswire/ — Regenerative Sciences, Inc., a company dedicated to advancing orthopedic care through non-surgical adult stem cell procedures, today announced the start of a new clinical research study on the use of autologous stem cells for treating knee osteoarthritis.

Photo – http://photos.prnewswire.com/prnh/20140314/PH83188LOGO-a

Photo – http://photos.prnewswire.com/prnh/20140314/PH83188-b

Complete information on this study, along with eligibility criteria can be found here: http://www.regenexx.com/chicago-knee-osteoarthritis-study-mitchell-sheinkop/

The study is being conducted in Chicago, Illinois in collaboration with Regenexx Physician Network Provider, Dr. Mitchell Sheinkop. Qualified candidates are currently being recruited for the study.

The Regenexx procedure utilizes a patient’s own stem cells to help repair a broad range of common injuries and degenerative conditions, including cartilage lesions, torn ligaments and tendons, osteoarthritis and bulging spinal discs. For many, the procedures offer a viable alternative to surgery. Regenexx patients experience little or no downtime following the procedure and avoid the lengthy rehabilitation period associated with most surgeries.

Knee osteoarthritis is one of the most common degenerative joint conditions in the U.S. today, affecting millions of individuals and resulting in approximately 700,000 knee replacements each year. The clinical research study, which is the first of its kind, will measure and compare patient outcomes following the Regenexx-SD, or “same day,” stem cell therapy against those from a control group of individuals undergoing exercise therapy and other non-surgical modalities, as well as historical results of patients who have undergone knee replacement surgery.

“Regenexx procedures are the most researched stem cell procedures in the United States and have been the subject of many published research papers on the use of stem cells for orthopedic conditions,” said Christopher J. Centeno, M.D., chief executive officer of Regenerative Sciences. “This study is a big step in quantifying the effectiveness of the procedure for knee osteoarthritis, with the added benefit of bringing additional awareness of regenerative stem cell treatments to both the medical community and the general public.”

“Regenerative Sciences continues to be at the forefront of regenerative orthopedic medicine in the United States,” said Dr. Mitchell Sheinkop, who is heading the Chicago study. “Having performed thousands of knee replacements during my 38 years as a joint replacement surgeon, I’m excited to be leading this important study. I have seen the ability of these new biologic treatments to help heal injuries and degenerative conditions without surgery and I believe they will soon become the new-normal for treating many orthopedic conditions.”

About Regenerative Sciences, LLC

Regenerative Sciences, LLC is an extension of the medical practice of the Centeno-Schultz clinic. We have developed patent-pending Regenexx procedures that use a person’s own stem cells and blood growth factors to help regenerate bone and cartilage. The physicians at Regenerative Sciences are dedicated to providing the option of non-surgical joint repair to patients. Headquartered in Colorado, Regenerative Sciences focuses on delivering high-quality treatment for people suffering from these often-debilitating diseases. We believe in educating patients, providing choices, offering options and encouraging people to take an active role in their own treatment. For more information on Regenerative Sciences and Regenexx procedures, visit: www.regenexx.com

Contact:
Marc Gutman
Stefanie Jones Public Relations
Email
phone: 303-578-6498

Read more news from Regenerative Sciences, LLC.

SOURCE Regenerative Sciences, Inc.


Source: PR Newswire



comments powered by Disqus